Intuitive Surgical Q1 2026 Earnings Beat Estimates on Strong Procedure Growth
Intuitive Surgical reported Q1 2026 results that beat Wall Street estimates, with total procedures growing 17% year-over-year, driven by broad adoption of da Vinci and Ion platforms.
Key Numbers
Intuitive Surgical (ISRG) reported first-quarter 2026 results that exceeded Wall Street expectations, driven by strong global procedure growth and expansion of its da Vinci and Ion platforms. CEO David Rosa attributed the performance to a 17% increase in total procedures, citing "broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care." The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding platform uptake.
Key Financial Results
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Revenue | Not yet disclosed | - |
| Net Income | Not yet disclosed | - |
| EPS | Not yet disclosed | - |
Note: Detailed financial figures were not available in the summary.
Highlights from the Release
- 17% procedure growth year-over-year.
- Expanding customer base for da Vinci and Ion.
- Improving procedure mix toward more complex cases.
Guidance
The company did not provide specific numerical guidance at this time.
Stock Impact
The earnings beat is expected to positively impact ISRG shares in upcoming trading sessions, given the continued procedure momentum.
What This Means for Investors
Intuitive Surgical's performance underscores strong demand for robotic surgery, reinforcing its competitive position. However, investors should await the full financial release to assess profitability and cash flow trends.
Frequently Asked Questions
Found this useful? Share it